{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T18:17:04Z","timestamp":1793902624075,"version":"4.8.0"},"reference-count":214,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Cancer"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1038\/s41568-026-00960-w","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:07:38Z","timestamp":1787242058000},"page":"854-872","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Brain barriers at the crossroads of glioma immune surveillance and immunotherapy response"],"prefix":"10.1038","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3059-9846","authenticated-orcid":false,"given":"Britta","family":"Engelhardt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4746-887X","authenticated-orcid":false,"given":"Michael","family":"Platten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,20]]},"reference":[{"key":"960_CR1","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/joim.13469","volume":"292","author":"ST Proulx","year":"2022","unstructured":"Proulx, S. T. & Engelhardt, B. Central nervous system zoning: how brain barriers establish subdivisions for CNS immune privilege and immune surveillance. J. Intern. Med. 292, 47\u201367 (2022). This review proposes that CNS immune privilege rests on the proper function of the brain barriers, which allow for CNS immune surveillance but prohibit activation of immune responses from the CNS parenchyma unless it is directly injured.","journal-title":"J. Intern. Med."},{"key":"960_CR2","first-page":"14","volume":"1","author":"Y Shirai","year":"1921","unstructured":"Shirai, Y. On the transplantation of the rat sarcoma in adult heterogenous animals. Jap. Med. World 1, 14\u201315 (1921).","journal-title":"Jap. Med. World"},{"key":"960_CR3","first-page":"58","volume":"29","author":"PB Medawar","year":"1948","unstructured":"Medawar, P. B. Immunity to homologous grafted skin; the fate of skin homografts transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye. Br. J. Exp. Pathol. 29, 58\u201369 (1948).","journal-title":"Br. J. Exp. Pathol."},{"key":"960_CR4","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1111\/j.1365-2990.1992.tb00811.x","volume":"18","author":"VH Perry","year":"1992","unstructured":"Perry, V. H. & Andersson, P. B. The inflammatory response in the CNS. Neuropathol. Appl. Neurobiol. 18, 454\u2013459 (1992).","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"960_CR5","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/nn.3062","volume":"15","author":"G Locatelli","year":"2012","unstructured":"Locatelli, G. et al. Primary oligodendrocyte death does not elicit anti-CNS immunity. Nat. Neurosci. 15, 543\u2013550 (2012).","journal-title":"Nat. Neurosci."},{"key":"960_CR6","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/nn.4193","volume":"19","author":"M Traka","year":"2016","unstructured":"Traka, M., Podojil, J. R., McCarthy, D. P., Miller, S. D. & Popko, B. Oligodendrocyte death results in immune-mediated CNS demyelination. Nat. Neurosci. 19, 65\u201374 (2016).","journal-title":"Nat. Neurosci."},{"key":"960_CR7","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1038\/nm.2514","volume":"17","author":"M Phillipson","year":"2011","unstructured":"Phillipson, M. & Kubes, P. The neutrophil in vascular inflammation. Nat. Med. 17, 1381\u20131390 (2011).","journal-title":"Nat. Med."},{"key":"960_CR8","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/0306-4522(86)90292-7","volume":"19","author":"DW Mason","year":"1986","unstructured":"Mason, D. W. et al. The fate of allogeneic and xenogeneic neuronal tissue transplanted into the third ventricle of rodents. Neuroscience 19, 685\u2013694 (1986).","journal-title":"Neuroscience"},{"key":"960_CR9","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/ni.3666","volume":"18","author":"B Engelhardt","year":"2017","unstructured":"Engelhardt, B., Vajkoczy, P. & Weller, R. O. The movers and shapers in immune privilege of the CNS. Nat. Immunol.18, 123\u2013131 (2017).","journal-title":"Nat. Immunol."},{"key":"960_CR10","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1113\/jphysiol.1980.sp013129","volume":"299","author":"MW Bradbury","year":"1980","unstructured":"Bradbury, M. W. & Cole, D. F. The role of the lymphatic system in drainage of cerebrospinal fluid and aqueous humour. J. Physiol. 299, 353\u2013365 (1980).","journal-title":"J. Physiol."},{"key":"960_CR11","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/0166-2236(86)90077-9","volume":"9","author":"H Wekerle","year":"1986","unstructured":"Wekerle, H., Linington, C., Lassmann, H. & Meyermann, R. Cellular immune reactivity within the CNS. Trends Neurosci. 9, 271\u2013277 (1986).","journal-title":"Trends Neurosci."},{"key":"960_CR12","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1002\/jnr.490280213","volume":"28","author":"WF Hickey","year":"1991","unstructured":"Hickey, W. F., Hsu, B. L. & Kimura, H. T-lymphocyte entry into the central nervous system. J. Neurosci. Res. 28, 254\u2013260 (1991).","journal-title":"J. Neurosci. Res."},{"key":"960_CR13","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1038\/s41593-023-01487-1","volume":"26","author":"JA Mazzitelli","year":"2023","unstructured":"Mazzitelli, J. A. et al. Skull bone marrow channels as immune gateways to the central nervous system. Nat. Neurosci. 26, 2052\u20132062 (2023).","journal-title":"Nat. Neurosci."},{"key":"960_CR14","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1097\/NEN.0b013e31818f9ca8","volume":"67","author":"T Owens","year":"2008","unstructured":"Owens, T., Bechmann, I. & Engelhardt, B. Perivascular spaces and the two steps to neuroinflammation. J. Neuropathol. Exp. Neurol. 67, 1113\u20131121 (2008).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"960_CR15","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/2045-8118-8-4","volume":"8","author":"B Engelhardt","year":"2011","unstructured":"Engelhardt, B. & Coisne, C. Fluids and barriers of the CNS establish immune privilege by confining immune surveillance to a two-walled castle moat surrounding the CNS castle. Fluids Barriers CNS 8, 4 (2011).","journal-title":"Fluids Barriers CNS"},{"key":"960_CR16","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1038\/s41586-018-0389-3","volume":"560","author":"JH Lee","year":"2018","unstructured":"Lee, J. H. et al. Human glioblastoma arises from subventricular zone cells with low-level driver mutations. Nature 560, 243\u2013247 (2018).","journal-title":"Nature"},{"key":"960_CR17","doi-asserted-by":"publisher","DOI":"10.1126\/science.adt0559","volume":"391","author":"JW Park","year":"2026","unstructured":"Park, J. W. et al. IDH-mutant gliomas arise from glial progenitor cells harboring the initial driver mutation. Science 391, eadt0559 (2026).","journal-title":"Science"},{"key":"960_CR18","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41572-024-00516-y","volume":"10","author":"M Weller","year":"2024","unstructured":"Weller, M. et al. Glioma. Nat. Rev. Dis. Primers 10, 33 (2024).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"960_CR19","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/nrneurol.2017.168","volume":"14","author":"M Preusser","year":"2018","unstructured":"Preusser, M., Brastianos, P. K. & Mawrin, C. Advances in meningioma genetics: novel therapeutic opportunities. Nat. Rev. Neurol. 14, 106\u2013115 (2018).","journal-title":"Nat. Rev. Neurol."},{"key":"960_CR20","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/S1286-0115(05)83235-7","volume":"89","author":"RO Weller","year":"2005","unstructured":"Weller, R. O. Microscopic morphology and histology of the human meninges. Morphologie 89, 22\u201334 (2005).","journal-title":"Morphologie"},{"key":"960_CR21","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1007\/BF00369291","volume":"79","author":"KH Andres","year":"1967","unstructured":"Andres, K. H. On the fine structure of the arachnoidea and dura mater of mammals. Z. Zellforsch. Mikrosk. Anat. 79, 272\u2013295 (1967).","journal-title":"Z. Zellforsch. Mikrosk. Anat."},{"key":"960_CR22","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1038\/s41593-024-01701-8","volume":"27","author":"C Betsholtz","year":"2024","unstructured":"Betsholtz, C. et al. Advances and controversies in meningeal biology. Nat. Neurosci. 27, 2056\u20132072 (2024).","journal-title":"Nat. Neurosci."},{"key":"960_CR23","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1007\/s00018-020-03706-5","volume":"78","author":"ST Proulx","year":"2021","unstructured":"Proulx, S. T. Cerebrospinal fluid outflow: a review of the historical and contemporary evidence for arachnoid villi, perineural routes, and dural lymphatics. Cell. Mol. Life Sci. 78, 2429\u20132457 (2021).","journal-title":"Cell. Mol. Life Sci."},{"key":"960_CR24","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1038\/s44161-025-00705-2","volume":"4","author":"DM McDonald","year":"2025","unstructured":"McDonald, D. M. et al. Cerebrospinal fluid draining lymphatics in health and disease: advances and controversies. Nat. Cardiovasc. Res. 4, 1047\u20131065 (2025).","journal-title":"Nat. Cardiovasc. Res."},{"key":"960_CR25","doi-asserted-by":"publisher","first-page":"3745","DOI":"10.1016\/j.neuron.2023.09.002","volume":"111","author":"R Pietila","year":"2023","unstructured":"Pietila, R. et al. Molecular anatomy of adult mouse leptomeninges. Neuron\u00a0111, 3745\u20133764\u00a0(2023).","journal-title":"Neuron"},{"key":"960_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-41580-4","volume":"14","author":"JA Mapunda","year":"2023","unstructured":"Mapunda, J. A. et al. VE-cadherin in arachnoid and pia mater cells serves as a suitable landmark for in vivo imaging of CNS immune surveillance and inflammation. Nat. Commun. 14, 5837 (2023).","journal-title":"Nat. Commun."},{"key":"960_CR27","doi-asserted-by":"publisher","first-page":"316","DOI":"10.3171\/jns.1986.65.3.0316","volume":"65","author":"M Hutchings","year":"1986","unstructured":"Hutchings, M. & Weller, R. O. Anatomical relationships of the pia mater to cerebral blood vessels in man. J. Neurosurg. 65, 316\u2013325 (1986).","journal-title":"J. Neurosurg."},{"key":"960_CR28","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s00401-018-1807-1","volume":"135","author":"J-F Ghersi-Egea","year":"2018","unstructured":"Ghersi-Egea, J.-F. et al. Molecular anatomy and functions of the choroidal blood-cerebrospinal fluid barrier in health and disease. Acta Neuropathol. 135, 337\u2013361 (2018).","journal-title":"Acta Neuropathol."},{"key":"960_CR29","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/s41593-025-02188-7","volume":"29","author":"D Verhaege","year":"2026","unstructured":"Verhaege, D. et al. Base barrier cells provide compartmentalization of choroid plexus, brain and CSF. Nat. Neurosci. 29, 551\u2013566 (2026).","journal-title":"Nat. Neurosci."},{"key":"960_CR30","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/cne.901640202","volume":"164","author":"S Nabeshima","year":"1975","unstructured":"Nabeshima, S., Reese, T. S., Landis, D. M. D. & Brightman, M. W. Junctions in the meninges and marginal glia. J. Comp. Neurol. 164, 127\u2013169 (1975).","journal-title":"J. Comp. Neurol."},{"key":"960_CR31","doi-asserted-by":"publisher","first-page":"5372","DOI":"10.3390\/ijms20215372","volume":"20","author":"M Castro Dias","year":"2019","unstructured":"Castro Dias, M., Mapunda, J. A., Vladymyrov, M. & Engelhardt, B. Structure and junctional complexes of endothelial, epithelial and glial brain barriers. Int. J. Mol. Sci. 20, 5372 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"960_CR32","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1002\/eji.201546272","volume":"46","author":"SM Tietz","year":"2016","unstructured":"Tietz, S. M. et al. Refined clinical scoring in comparative EAE studies does not enhance the chance to observe statistically significant differences. Eur. J. Immunol. 46, 2481\u20132483 (2016).","journal-title":"Eur. J. Immunol."},{"key":"960_CR33","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/nature25739","volume":"554","author":"Vanlandewijck","year":"2018","unstructured":"Vanlandewijck et al. A molecular atlas of cell types and zonation in the brain vasculature. Nature 554, 475\u2013480 (2018).","journal-title":"Nature"},{"key":"960_CR34","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s00401-018-1815-1","volume":"135","author":"S Liebner","year":"2018","unstructured":"Liebner, S. et al. Functional morphology of the blood-brain barrier in health and disease. Acta Neuropathol. 135, 311\u2013336 (2018).","journal-title":"Acta Neuropathol."},{"key":"960_CR35","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/jnc.15599","volume":"161","author":"Y Uchida","year":"2022","unstructured":"Uchida, Y. et al. A human blood-arachnoid barrier atlas of transporters, receptors, enzymes, and tight junction and marker proteins: comparison with dog and pig in absolute abundance. J. Neurochem. 161, 187\u2013208 (2022).","journal-title":"J. Neurochem."},{"key":"960_CR36","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1002\/glia.20642","volume":"56","author":"M Bundgaard","year":"2008","unstructured":"Bundgaard, M. & Abbott, N. J. All vertebrates started out with a glial blood-brain barrier 4-500 million years ago. Glia 56, 699\u2013708 (2008). This article provides evidence that the ancestral vertebrate BBB was astrocyte based, with the later evolution of an endothelial barrier conferring selective advantage and shaping the development, function and pathology of mammalian CNS barrier layers.","journal-title":"Glia"},{"key":"960_CR37","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1084\/jem.20051342","volume":"203","author":"S Agrawal","year":"2006","unstructured":"Agrawal, S. et al. Dystroglycan is selectively cleaved at the parenchymal basement membrane at sites of leukocyte extravasation in experimental autoimmune encephalomyelitis. J. Exp. Med. 203, 1007\u20131019 (2006).","journal-title":"J. Exp. Med."},{"key":"960_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-63945-7","volume":"16","author":"P Helie-Legoupil","year":"2025","unstructured":"Helie-Legoupil, P. et al. In vivo imaging of the barrier properties of the glia limitans during health and neuroinflammation. Nat. Commun. 16, 8895 (2025). This study introduces a fluorescent reporter mouse for the glia limitans and provides direct evidence for the barrier properties of the glia limitans in vivo.","journal-title":"Nat. Commun."},{"key":"960_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21117-3","volume":"12","author":"E Jung","year":"2021","unstructured":"Jung, E. et al. Tumor cell plasticity, heterogeneity, and resistance in crucial microenvironmental niches in glioma. Nat. Commun. 12, 1014 (2021).","journal-title":"Nat. Commun."},{"key":"960_CR40","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/nature23666","volume":"549","author":"X Lan","year":"2017","unstructured":"Lan, X. et al. Fate mapping of human glioblastoma reveals an invariant stem cell hierarchy. Nature 549, 227\u2013232 (2017).","journal-title":"Nature"},{"key":"960_CR41","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.devcel.2015.01.010","volume":"32","author":"S Bjornsson Christopher","year":"2015","unstructured":"Bjornsson Christopher, S., Apostolopoulou, M., Tian, Y. & Temple, S. It takes a village: constructing the neurogenic niche. Dev. Cell 32, 435\u2013446 (2015).","journal-title":"Dev. Cell"},{"key":"960_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-61999-1","volume":"16","author":"M Doroszko","year":"2025","unstructured":"Doroszko, M. et al. The invasion phenotypes of glioblastoma depend on plastic and reprogrammable cell states. Nat. Commun. 16, 6662 (2025).","journal-title":"Nat. Commun."},{"key":"960_CR43","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/s41571-019-0181-9","volume":"16","author":"EA Kuczynski","year":"2019","unstructured":"Kuczynski, E. A., Vermeulen, P. B., Pezzella, F., Kerbel, R. S. & Reynolds, A. R. Vessel co-option in cancer. Nat. Rev. Clin. Oncol. 16, 469\u2013493 (2019).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"960_CR44","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s10456-019-09691-z","volume":"23","author":"G Seano","year":"2020","unstructured":"Seano, G. & Jain, R. K. Vessel co-option in glioblastoma: emerging insights and opportunities. Angiogenesis 23, 9\u201316 (2020).","journal-title":"Angiogenesis"},{"key":"960_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-47985-z","volume":"15","author":"C Pichol-Thievend","year":"2024","unstructured":"Pichol-Thievend, C. et al. VC-resist glioblastoma cell state: vessel co-option as a key driver of chemoradiation resistance. Nat. Commun. 15, 3602 (2024).","journal-title":"Nat. Commun."},{"key":"960_CR46","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.cell.2013.02.021","volume":"153","author":"L Cheng","year":"2013","unstructured":"Cheng, L. et al. Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth. Cell 153, 139\u2013152 (2013).","journal-title":"Cell"},{"key":"960_CR47","doi-asserted-by":"publisher","first-page":"702","DOI":"10.3171\/jns.2005.103.4.0702","volume":"103","author":"H Bernsen","year":"2005","unstructured":"Bernsen, H., Van der Laak, J., Kusters, B., Van der Ven, A. & Wesseling, P. Gliomatosis cerebri: quantitative proof of vessel recruitment by cooptation instead of angiogenesis. J. Neurosurg. 103, 702\u2013706 (2005).","journal-title":"J. Neurosurg."},{"key":"960_CR48","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.3390\/pharmaceutics12121205","volume":"12","author":"JI Griffith","year":"2020","unstructured":"Griffith, J. I. et al. Addressing BBB heterogeneity: a new paradigm for drug delivery to brain tumors. Pharmaceutics 12, 1205 (2020).","journal-title":"Pharmaceutics"},{"key":"960_CR49","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41568-019-0205-x","volume":"20","author":"CD Arvanitis","year":"2020","unstructured":"Arvanitis, C. D., Ferraro, G. B. & Jain, R. K. The blood-brain barrier and blood-tumour barrier in brain tumours and metastases. Nat. Rev. Cancer 20, 26\u201341 (2020).","journal-title":"Nat. Rev. Cancer"},{"key":"960_CR50","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/BF00598951","volume":"34","author":"M Watanabe","year":"1992","unstructured":"Watanabe, M., Tanaka, R. & Takeda, N. Magnetic resonance imaging and histopathology of cerebral gliomas. Neuroradiology 34, 463\u2013469 (1992).","journal-title":"Neuroradiology"},{"key":"960_CR51","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1093\/neuonc\/noaf204","volume":"28","author":"JH Oh","year":"2026","unstructured":"Oh, J. H. et al. Window of opportunity evaluation of blood-brain barrier permeability heterogeneity within and across high-grade glioma patients. Neuro Oncol. 28, 130\u2013142 (2026).","journal-title":"Neuro Oncol."},{"key":"960_CR52","doi-asserted-by":"publisher","first-page":"jcs253880","DOI":"10.1242\/jcs.253880","volume":"134","author":"M Castro Dias","year":"2021","unstructured":"Castro Dias, M. et al. Brain endothelial tricellular junctions as novel sites for T cell diapedesis across the blood-brain barrier. J. Cell Sci. 134, jcs253880 (2021).","journal-title":"J. Cell Sci."},{"key":"960_CR53","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s00401-016-1606-5","volume":"132","author":"B Engelhardt","year":"2016","unstructured":"Engelhardt, B. et al. Vascular, glial, and lymphatic immune gateways of the central nervous system. Acta Neuropathol. 132, 317\u2013338 (2016).","journal-title":"Acta Neuropathol."},{"key":"960_CR54","doi-asserted-by":"publisher","first-page":"H1","DOI":"10.1530\/VB-19-0033","volume":"2","author":"L Marchetti","year":"2020","unstructured":"Marchetti, L. & Engelhardt, B. Immune cell trafficking across the blood-brain barrier in the absence and presence of neuroinflammation. Vasc. Biol. 2, H1\u2013H18 (2020).","journal-title":"Vasc. Biol."},{"key":"960_CR55","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/ni.3423","volume":"17","author":"T Goldmann","year":"2016","unstructured":"Goldmann, T. et al. Origin, fate and dynamics of macrophages at central nervous system interfaces. Nat. Immunol. 17, 797\u2013805 (2016).","journal-title":"Nat. Immunol."},{"key":"960_CR56","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/s41583-019-0201-x","volume":"20","author":"K Kierdorf","year":"2019","unstructured":"Kierdorf, K., Masuda, T., Jord\u00e3o, M. J. C. & Prinz, M. Macrophages at CNS interfaces: ontogeny and function in health and disease. Nat. Rev. Neurosci. 20, 547\u2013562 (2019).","journal-title":"Nat. Rev. Neurosci."},{"key":"960_CR57","doi-asserted-by":"publisher","first-page":"609921","DOI":"10.3389\/fimmu.2020.609921","volume":"11","author":"DC Ivan","year":"2020","unstructured":"Ivan, D. C., Walthert, S., Berve, K., Steudler, J. & Locatelli, G. Dwellers and trespassers: mononuclear phagocytes at the borders of the central nervous system. Front. Immunol. 11, 609921 (2020).","journal-title":"Front. Immunol."},{"key":"960_CR58","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/s41586-022-04596-2","volume":"604","author":"T Masuda","year":"2022","unstructured":"Masuda, T. et al. Specification of CNS macrophage subsets occurs postnatally in defined niches. Nature 604, 740\u2013748 (2022).","journal-title":"Nature"},{"key":"960_CR59","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.pneurobio.2017.05.002","volume":"156","author":"JA Coles","year":"2017","unstructured":"Coles, J. A., Myburgh, E., Brewer, J. M. & McMenamin, P. G. Where are we? The anatomy of the murine cortical meninges revisited for intravital imaging, immunology, and clearance of waste from the brain. Prog. Neurobiol. 156, 107\u2013148 (2017).","journal-title":"Prog. Neurobiol."},{"key":"960_CR60","doi-asserted-by":"publisher","first-page":"eaau8380","DOI":"10.1126\/sciimmunol.aau8380","volume":"4","author":"S Mundt","year":"2019","unstructured":"Mundt, S. et al. Conventional DCs sample and present myelin antigens in the healthy CNS and allow parenchymal T cell entry to initiate neuroinflammation. Sci. Immunol. 4, eaau8380 (2019).","journal-title":"Sci. Immunol."},{"key":"960_CR61","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1038\/nm.3182","volume":"19","author":"D Lodygin","year":"2013","unstructured":"Lodygin, D. et al. A combination of fluorescent NFAT and H2B sensors uncovers dynamics of T cell activation in real time during CNS autoimmunity. Nat. Med. 19, 784\u2013790 (2013).","journal-title":"Nat. Med."},{"key":"960_CR62","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.matbio.2017.11.007","volume":"75\u201376","author":"MJ Hannocks","year":"2019","unstructured":"Hannocks, M. J. et al. The gelatinases, MMP-2 and MMP-9, as fine tuners of neuroinflammatory processes. Matrix Biol. 75\u201376, 102\u2013113 (2019). This study identified molecular mechanisms involved in T cell migration across the glia limitans in the context of autoimmune neuroinflammation in a mouse model.","journal-title":"Matrix Biol."},{"key":"960_CR63","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12987-023-00441-4","volume":"20","author":"I Lazarevic","year":"2023","unstructured":"Lazarevic, I. et al. The choroid plexus acts as an immune cell reservoir and brain entry site in experimental autoimmune encephalomyelitis. Fluids Barriers CNS 20, 39 (2023).","journal-title":"Fluids Barriers CNS"},{"key":"960_CR64","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1002\/1097-0029(20010101)52:1<112::AID-JEMT13>3.0.CO;2-5","volume":"52","author":"B Engelhardt","year":"2001","unstructured":"Engelhardt, B., Wolburg-Buchholz, K. & Wolburg, H. Involvement of the choroid plexus in central nervous system inflammation. Microsc. Res. Tech. 52, 112\u2013129 (2001).","journal-title":"Microsc. Res. Tech."},{"key":"960_CR65","doi-asserted-by":"publisher","first-page":"eabf7844","DOI":"10.1126\/science.abf7844","volume":"373","author":"A Cugurra","year":"2021","unstructured":"Cugurra, A. et al. Skull and vertebral bone marrow are myeloid cell reservoirs for the meninges and CNS parenchyma. Science 373, eabf7844 (2021).","journal-title":"Science"},{"key":"960_CR66","doi-asserted-by":"publisher","first-page":"eabf9277","DOI":"10.1126\/science.abf9277","volume":"373","author":"S Brioschi","year":"2021","unstructured":"Brioschi, S. et al. Heterogeneity of meningeal B cells reveals a lymphopoietic niche at the CNS borders. Science 373, eabf9277 (2021).","journal-title":"Science"},{"key":"960_CR67","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1038\/s41593-021-00880-y","volume":"24","author":"D Schafflick","year":"2021","unstructured":"Schafflick, D. et al. Single-cell profiling of CNS border compartment leukocytes reveals that B cells and their progenitors reside in non-diseased meninges. Nat. Neurosci. 24, 1225\u20131234 (2021).","journal-title":"Nat. Neurosci."},{"key":"960_CR68","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1038\/s41593-018-0213-2","volume":"21","author":"F Herisson","year":"2018","unstructured":"Herisson, F. et al. Direct vascular channels connect skull bone marrow and the brain surface enabling myeloid cell migration. Nat. Neurosci. 21, 1209\u20131217 (2018).","journal-title":"Nat. Neurosci."},{"key":"960_CR69","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/s41593-018-0301-3","volume":"22","author":"R Cai","year":"2019","unstructured":"Cai, R. et al. Panoptic imaging of transparent mice reveals whole-body neuronal projections and skull-meninges connections. Nat. Neurosci. 22, 317\u2013327 (2019).","journal-title":"Nat. Neurosci."},{"key":"960_CR70","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/d41586-021-01962-4","volume":"596","author":"B Engelhardt","year":"2021","unstructured":"Engelhardt, B. Private immune protection at the border of the central nervous system. Nature 596, 38\u201340 (2021).","journal-title":"Nature"},{"key":"960_CR71","doi-asserted-by":"publisher","first-page":"3706","DOI":"10.1016\/j.cell.2023.07.009","volume":"186","author":"ZI Kolabas","year":"2023","unstructured":"Kolabas, Z. I. et al. Distinct molecular profiles of skull bone marrow in health and neurological disorders. Cell 186, 3706\u20133725 (2023).","journal-title":"Cell"},{"key":"960_CR72","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/s41586-023-06993-7","volume":"627","author":"LCD Smyth","year":"2024","unstructured":"Smyth, L. C. D. et al. Identification of direct connections between the dura and the brain. Nature 627, 165\u2013173 (2024).","journal-title":"Nature"},{"key":"960_CR73","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1084\/jem.20142290","volume":"212","author":"A Aspelund","year":"2015","unstructured":"Aspelund, A. et al. A dural lymphatic vascular system that drains brain interstitial fluid and macromolecules. J. Exp. Med. 212, 991\u2013999 (2015).","journal-title":"J. Exp. Med."},{"key":"960_CR74","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/nature14432","volume":"523","author":"A Louveau","year":"2015","unstructured":"Louveau, A. et al. Structural and functional features of central nervous system lymphatic vessels. Nature 523, 337\u2013341 (2015).","journal-title":"Nature"},{"key":"960_CR75","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.stem.2008.07.025","volume":"3","author":"M Tavazoie","year":"2008","unstructured":"Tavazoie, M. et al. A specialized vascular niche for adult neural stem cells. Cell Stem Cell 3, 279\u2013288 (2008).","journal-title":"Cell Stem Cell"},{"key":"960_CR76","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1016\/j.ccell.2018.03.020","volume":"33","author":"A Griveau","year":"2018","unstructured":"Griveau, A. et al. A glial signature and Wnt7 signaling regulate glioma-vascular interactions and tumor microenvironment. Cancer Cell 33, 874\u2013889 (2018).","journal-title":"Cancer Cell"},{"key":"960_CR77","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms5196","volume":"5","author":"S Watkins","year":"2014","unstructured":"Watkins, S. et al. Disruption of astrocyte-vascular coupling and the blood-brain barrier by invading glioma cells. Nat. Commun. 5, 4196 (2014).","journal-title":"Nat. Commun."},{"key":"960_CR78","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/s41591-023-02673-1","volume":"30","author":"R Sankowski","year":"2024","unstructured":"Sankowski, R. et al. Multiomic spatial landscape of innate immune cells at human central nervous system borders. Nat. Med. 30, 186\u2013198 (2024).","journal-title":"Nat. Med."},{"key":"960_CR79","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1038\/s41586-025-08633-8","volume":"640","author":"TE Miller","year":"2025","unstructured":"Miller, T. E. et al. Programs, origins and immunomodulatory functions of myeloid cells in glioma. Nature 640, 1072\u20131082 (2025).","journal-title":"Nature"},{"key":"960_CR80","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.cell.2023.11.032","volume":"187","author":"D Kirschenbaum","year":"2024","unstructured":"Kirschenbaum, D. et al. Time-resolved single-cell transcriptomics defines immune trajectories in glioblastoma. Cell 187, 149\u2013165 (2024).","journal-title":"Cell"},{"key":"960_CR81","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.ccr.2008.01.034","volume":"13","author":"R Du","year":"2008","unstructured":"Du, R. et al. HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 13, 206\u2013220 (2008).","journal-title":"Cancer Cell"},{"key":"960_CR82","doi-asserted-by":"publisher","first-page":"114250","DOI":"10.1016\/j.celrep.2024.114250","volume":"43","author":"A Patir","year":"2024","unstructured":"Patir, A. et al. Phenotypic and spatial heterogeneity of brain myeloid cells after stroke is associated with cell ontogeny, tissue damage, and brain connectivity. Cell Rep. 43, 114250 (2024).","journal-title":"Cell Rep."},{"key":"960_CR83","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1038\/s41588-025-02167-5","volume":"57","author":"M Nomura","year":"2025","unstructured":"Nomura, M. et al. The multilayered transcriptional architecture of glioblastoma ecosystems. Nat. Genet. 57, 1155\u20131167\u00a0(2025). This paper provides a spatially resolved map of tumour cell states of glioblastoma defining distinct ecosystems.","journal-title":"Nat. Genet."},{"key":"960_CR84","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/nri1130","volume":"3","author":"RM Ransohoff","year":"2003","unstructured":"Ransohoff, R. M., Kivis\u00e4kk, P. & Kidd, G. Three or more routes for leukocyte migration into the central nervous system. Nat. Rev. Immunol. 3, 569\u2013581 (2003).","journal-title":"Nat. Rev. Immunol."},{"key":"960_CR85","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-51063-6","volume":"9","author":"B Weenink","year":"2019","unstructured":"Weenink, B. et al. Low-grade glioma harbors few CD8 T cells, which is accompanied by decreased expression of chemo-attractants, not immunogenic antigens. Sci. Rep. 9, 14643 (2019).","journal-title":"Sci. Rep."},{"key":"960_CR86","doi-asserted-by":"publisher","first-page":"2947","DOI":"10.1038\/s41591-024-03152-x","volume":"30","author":"C Dobersalske","year":"2024","unstructured":"Dobersalske, C. et al. Cranioencephalic functional lymphoid units in glioblastoma. Nat. Med. 30, 2947\u20132956 (2024). This paper provides evidence that cranial bone marrow, in juxtaposition to treatment-naive glioblastoma tumours, harbours tumour-reactive T cells at the time of initial diagnosis.","journal-title":"Nat. Med."},{"key":"960_CR87","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/s41587-024-02161-y","volume":"43","author":"CL Tan","year":"2025","unstructured":"Tan, C. L. et al. Prediction of tumor-reactive T cell receptors from scRNA-seq data for personalized T cell therapy. Nat. Biotechnol. 43, 134\u2013142 (2025).","journal-title":"Nat. Biotechnol."},{"key":"960_CR88","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1038\/s41591-018-0135-2","volume":"24","author":"P Chongsathidkiet","year":"2018","unstructured":"Chongsathidkiet, P. et al. Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors. Nat. Med. 24, 1459\u20131468 (2018).","journal-title":"Nat. Med."},{"key":"960_CR89","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/s41422-020-0287-8","volume":"30","author":"X Hu","year":"2020","unstructured":"Hu, X. et al. Meningeal lymphatic vessels regulate brain tumor drainage and immunity. Cell Res. 30, 229\u2013243 (2020).","journal-title":"Cell Res."},{"key":"960_CR90","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/s41586-019-1912-x","volume":"577","author":"E Song","year":"2020","unstructured":"Song, E. et al. VEGF-C-driven lymphatic drainage enables immunosurveillance of brain tumours. Nature 577, 689\u2013694 (2020).","journal-title":"Nature"},{"key":"960_CR91","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/s41586-024-07130-8","volume":"628","author":"X Yin","year":"2024","unstructured":"Yin, X. et al. Compartmentalized ocular lymphatic system mediates eye-brain immunity. Nature 628, 204\u2013211 (2024).","journal-title":"Nature"},{"key":"960_CR92","doi-asserted-by":"publisher","first-page":"vdab147","DOI":"10.1093\/noajnl\/vdab147","volume":"3","author":"J Blobner","year":"2021","unstructured":"Blobner, J. et al. Comparative evaluation of T-cell receptors in experimental glioma-draining lymph nodes. Neuro Oncol. Adv. 3, vdab147 (2021).","journal-title":"Neuro Oncol. Adv."},{"key":"960_CR93","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1093\/neuonc\/noac055","volume":"24","author":"EC Cordell","year":"2022","unstructured":"Cordell, E. C., Alghamri, M. S., Castro, M. G. & Gutmann, D. H. T lymphocytes as dynamic regulators of glioma pathobiology. Neuro Oncol. 24, 1647\u20131657 (2022).","journal-title":"Neuro Oncol."},{"key":"960_CR94","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/s43018-021-00201-z","volume":"2","author":"M Friedrich","year":"2021","unstructured":"Friedrich, M. et al. Tryptophan metabolism drives dynamic immunosuppressive myeloid states in IDH-mutant gliomas. Nat. Cancer 2, 723\u2013740 (2021).","journal-title":"Nat. Cancer"},{"key":"960_CR95","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1016\/j.cell.2021.01.022","volume":"184","author":"ND Mathewson","year":"2021","unstructured":"Mathewson, N. D. et al. Inhibitory CD161 receptor identified in glioma-infiltrating T cells by single-cell analysis. Cell 184, 1281\u20131298 (2021).","journal-title":"Cell"},{"key":"960_CR96","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28523-1","volume":"13","author":"VM Ravi","year":"2022","unstructured":"Ravi, V. M. et al. T-cell dysfunction in the glioblastoma microenvironment is mediated by myeloid cells releasing interleukin-10. Nat. Commun. 13, 925 (2022).","journal-title":"Nat. Commun."},{"key":"960_CR97","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.ccell.2022.12.007","volume":"41","author":"M Kilian","year":"2023","unstructured":"Kilian, M. et al. MHC class II-restricted antigen presentation is required to prevent dysfunction of cytotoxic T cells by blood-borne myeloids in brain tumors. Cancer Cell 41, 235\u2013251 (2023).","journal-title":"Cancer Cell"},{"key":"960_CR98","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1038\/s41591-018-0095-6","volume":"24","author":"L Bunse","year":"2018","unstructured":"Bunse, L. et al. Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate. Nat. Med. 24, 1192\u20131203 (2018).","journal-title":"Nat. Med."},{"key":"960_CR99","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1126\/science.abj5104","volume":"377","author":"G Notarangelo","year":"2022","unstructured":"Notarangelo, G. et al. Oncometabolite d-2HG alters T cell metabolism to impair CD8+ T cell function. Science 377, 1519\u20131529 (2022).","journal-title":"Science"},{"key":"960_CR100","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0019823","volume":"6","author":"CA Opitz","year":"2011","unstructured":"Opitz, C. A. et al. The indoleamine-2,3-dioxygenase (IDO) inhibitor 1-methyl-D-tryptophan upregulates IDO1 in human cancer cells. PLoS ONE 6, e19823 (2011).","journal-title":"PLoS ONE"},{"key":"960_CR101","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/nature10491","volume":"478","author":"CA Opitz","year":"2011","unstructured":"Opitz, C. A. et al. An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature 478, 197\u2013203 (2011).","journal-title":"Nature"},{"key":"960_CR102","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1093\/neuonc\/noz080","volume":"21","author":"X Guo","year":"2019","unstructured":"Guo, X., Pan, Y. & Gutmann, D. H. Genetic and genomic alterations differentially dictate low-grade glioma growth through cancer stem cell-specific chemokine recruitment of T cells and microglia. Neuro Oncol. 21, 1250\u20131262 (2019).","journal-title":"Neuro Oncol."},{"key":"960_CR103","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1093\/neuonc\/nos014","volume":"14","author":"CA Crane","year":"2012","unstructured":"Crane, C. A., Ahn, B. J., Han, S. J. & Parsa, A. T. Soluble factors secreted by glioblastoma cell lines facilitate recruitment, survival, and expansion of regulatory T cells: implications for immunotherapy. Neuro Oncol. 14, 584\u2013595 (2012).","journal-title":"Neuro Oncol."},{"key":"960_CR104","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-14642-0","volume":"11","author":"K Aslan","year":"2020","unstructured":"Aslan, K. et al. Heterogeneity of response to immune checkpoint blockade in hypermutated experimental gliomas. Nat. Commun. 11, 931 (2020).","journal-title":"Nat. Commun."},{"key":"960_CR105","doi-asserted-by":"publisher","first-page":"e116","DOI":"10.1200\/EDBK_100005","volume":"35","author":"AS Berghoff","year":"2016","unstructured":"Berghoff, A. S., Venur, V. A., Preusser, M. & Ahluwalia, M. S. Immune checkpoint inhibitors in brain metastases: from biology to treatment. Am. Soc. Clin. Oncol. Educ. Book 35, e116\u2013e122 (2016).","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"960_CR106","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41568-019-0224-7","volume":"20","author":"JH Sampson","year":"2020","unstructured":"Sampson, J. H., Gunn, M. D., Fecci, P. E. & Ashley, D. M. Brain immunology and immunotherapy in brain tumours. Nat. Rev. Cancer 20, 12\u201325 (2020).","journal-title":"Nat. Rev. Cancer"},{"key":"960_CR107","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1093\/neuonc\/noac116","volume":"24","author":"M Lim","year":"2022","unstructured":"Lim, M. et al. Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter. Neuro Oncol. 24, 1935\u20131949 (2022).","journal-title":"Neuro Oncol."},{"key":"960_CR108","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1093\/neuonc\/noac099","volume":"25","author":"A Omuro","year":"2023","unstructured":"Omuro, A. et al. Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: an international randomized phase III trial. Neuro Oncol. 25, 123\u2013134 (2023).","journal-title":"Neuro Oncol."},{"key":"960_CR109","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1200\/JCO.2016.66.6552","volume":"34","author":"E Bouffet","year":"2016","unstructured":"Bouffet, E. et al. Immune checkpoint inhibition for hypermutant glioblastoma multiforme resulting from germline biallelic mismatch repair deficiency. J. Clin. Oncol. 34, 2206\u20132211 (2016).","journal-title":"J. Clin. Oncol."},{"key":"960_CR110","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1158\/2159-8290.CD-23-0559","volume":"14","author":"A Das","year":"2024","unstructured":"Das, A. et al. Combined immunotherapy improves outcome for replication-repair-deficient (RRD) high-grade glioma failing anti-PD-1 monotherapy: a report from the international RRD consortium. Cancer Discov. 14, 258\u2013273 (2024). This paper provides evidence that immune checkpoint inhibitor combinations provide clinical benefit in selected patients with glioblastoma and replication repair deficiency.","journal-title":"Cancer Discov."},{"key":"960_CR111","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s42466-022-00184-x","volume":"4","author":"L Bunse","year":"2022","unstructured":"Bunse, L. et al. AMPLIFY-NEOVAC: a randomized, 3-arm multicenter phase I trial to assess safety, tolerability and immunogenicity of IDH1-vac combined with an immune checkpoint inhibitor targeting programmed death-ligand 1 in isocitrate dehydrogenase 1 mutant gliomas. Neurol. Res. Pract. 4, 20 (2022).","journal-title":"Neurol. Res. Pract."},{"key":"960_CR112","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1158\/2159-8290.CD-16-0575","volume":"6","author":"TM Johanns","year":"2016","unstructured":"Johanns, T. M. et al. Immunogenomics of hypermutated glioblastoma: a patient with germline POLE deficiency treated with checkpoint blockade immunotherapy. Cancer Discov. 6, 1230\u20131236 (2016).","journal-title":"Cancer Discov."},{"key":"960_CR113","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-024-00597-8","volume":"8","author":"H Palova","year":"2024","unstructured":"Palova, H. et al. Precision immuno-oncology approach for four malignant tumors in siblings with constitutional mismatch repair deficiency syndrome. npj Precis. Oncol. 8, 110 (2024).","journal-title":"npj Precis. Oncol."},{"key":"960_CR114","doi-asserted-by":"publisher","first-page":"4770","DOI":"10.1158\/1078-0432.CCR-23-0411","volume":"29","author":"A Das","year":"2023","unstructured":"Das, A. et al. Efficacy of nivolumab in pediatric cancers with high mutation burden and mismatch repair deficiency. Clin. Cancer Res. 29, 4770\u20134783 (2023).","journal-title":"Clin. Cancer Res."},{"key":"960_CR115","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1016\/j.ccell.2023.09.013","volume":"41","author":"B Zhao","year":"2023","unstructured":"Zhao, B., Kilian, M., Bunse, T., Platten, M. & Bunse, L. Tumor-reactive T helper cells in the context of vaccination against glioma. Cancer Cell 41, 1829\u20131834 (2023).","journal-title":"Cancer Cell"},{"key":"960_CR116","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1200\/JCO.22.02616","volume":"41","author":"M Platten","year":"2023","unstructured":"Platten, M. & Grassl, N. Vaccines targeting gliomas: antigens matter. J. Clin. Oncol. 41, 1466\u20131469 (2023).","journal-title":"J. Clin. Oncol."},{"key":"960_CR117","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1093\/brain\/aws042","volume":"135","author":"V Dutoit","year":"2012","unstructured":"Dutoit, V. et al. Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy. Brain 135, 1042\u20131054 (2012).","journal-title":"Brain"},{"key":"960_CR118","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/s41586-018-0810-y","volume":"565","author":"N Hilf","year":"2019","unstructured":"Hilf, N. et al. Actively personalized vaccination trial for newly diagnosed glioblastoma. Nature 565, 240\u2013245 (2019). This clinical trial demonstrates feasibility and safety of a targeted vaccine approach in patients with glioblastoma and shows that vaccine-induced T cells home to brain tumours.","journal-title":"Nature"},{"key":"960_CR119","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41586-018-0792-9","volume":"565","author":"DB Keskin","year":"2019","unstructured":"Keskin, D. B. et al. Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature 565, 234\u2013239 (2019).","journal-title":"Nature"},{"key":"960_CR120","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/S1470-2045(17)30517-X","volume":"18","author":"M Weller","year":"2017","unstructured":"Weller, M. et al. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. Lancet Oncol. 18, 1373\u20131385 (2017).","journal-title":"Lancet Oncol."},{"key":"960_CR121","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1093\/neuonc\/nox167","volume":"19","author":"M Platten","year":"2017","unstructured":"Platten, M. EGFRvIII vaccine in glioblastoma-InACT-IVe or not ReACTive enough? Neuro Oncol. 19, 1425\u20131426 (2017).","journal-title":"Neuro Oncol."},{"key":"960_CR122","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-16726-x","volume":"12","author":"C Taylor","year":"2022","unstructured":"Taylor, C., Ekert, J. O., Sefcikova, V., Fersht, N. & Samandouras, G. Discriminators of pseudoprogression and true progression in high-grade gliomas: a systematic review and meta-analysis. Sci. Rep. 12, 13258 (2022).","journal-title":"Sci. Rep."},{"key":"960_CR123","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1038\/nature13387","volume":"512","author":"T Schumacher","year":"2014","unstructured":"Schumacher, T. et al. A vaccine targeting mutant IDH1 induces antitumour immunity. Nature 512, 324\u2013327 (2014).","journal-title":"Nature"},{"key":"960_CR124","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1038\/s41591-023-02555-6","volume":"29","author":"N Grassl","year":"2023","unstructured":"Grassl, N. et al. A H3K27M-targeted vaccine in adults with diffuse midline glioma. Nat. Med. 29, 2586\u20132592 (2023).","journal-title":"Nat. Med."},{"key":"960_CR125","doi-asserted-by":"publisher","first-page":"5125","DOI":"10.1016\/j.cell.2025.06.019","volume":"188","author":"E Blass","year":"2025","unstructured":"Blass, E. et al. A multi-adjuvant personal neoantigen vaccine generates potent immunity in melanoma. Cell\u00a0188, 5125\u20135141\u00a0(2025).","journal-title":"Cell"},{"key":"960_CR126","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/s41586-021-03363-z","volume":"592","author":"M Platten","year":"2021","unstructured":"Platten, M. et al. A vaccine targeting mutant IDH1 in newly diagnosed glioma. Nature 592, 463\u2013468 (2021). This clinical trial demonstrates feasibility and safety of a vaccine targeting a recurrent clonal driver mutation in patients with glioma and shows that vaccine-induced T cells home to brain tumours.","journal-title":"Nature"},{"key":"960_CR127","doi-asserted-by":"publisher","first-page":"eadi9091","DOI":"10.1126\/sciadv.adi9091","volume":"10","author":"T Boschert","year":"2024","unstructured":"Boschert, T. et al. H3K27M neoepitope vaccination in diffuse midline glioma induces B and T cell responses across diverse HLA loci of a recovered patient. Sci. Adv. 10, eadi9091 (2024).","journal-title":"Sci. Adv."},{"key":"960_CR128","doi-asserted-by":"publisher","first-page":"e512","DOI":"10.1016\/S1470-2045(24)00190-6","volume":"25","author":"KM Hotchkiss","year":"2024","unstructured":"Hotchkiss, K. M. et al. A brave new framework for glioma drug development. Lancet Oncol. 25, e512\u2013e519 (2024).","journal-title":"Lancet Oncol."},{"key":"960_CR129","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1038\/s41591-023-02464-8","volume":"29","author":"K Singh","year":"2023","unstructured":"Singh, K. et al. Correcting the drug development paradigm for glioblastoma requires serial tissue sampling. Nat. Med. 29, 2402\u20132405 (2023).","journal-title":"Nat. Med."},{"key":"960_CR130","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1158\/1078-0432.CCR-21-2681","volume":"28","author":"K Singh","year":"2022","unstructured":"Singh, K. et al. Designing clinical trials for combination immunotherapy: a framework for glioblastoma. Clin. Cancer Res. 28, 585\u2013593 (2022).","journal-title":"Clin. Cancer Res."},{"key":"960_CR131","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-012216","volume":"13","author":"K Lindner","year":"2025","unstructured":"Lindner, K. et al. ESPEC-SUIT: a versatile and robust platform to identify and track antigen-specific T cell receptors in patients with cancer. J. Immunother. Cancer 13, e012216 (2025).","journal-title":"J. Immunother. Cancer"},{"key":"960_CR132","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s42466-023-00282-4","volume":"5","author":"N Grassl","year":"2023","unstructured":"Grassl, N. et al. INTERCEPT H3: a multicenter phase I peptide vaccine trial for the treatment of H3-mutated diffuse midline gliomas. Neurol. Res. Pract. 5, 55 (2023).","journal-title":"Neurol. Res. Pract."},{"key":"960_CR133","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1093\/neuonc\/noae225","volume":"27","author":"G Tabatabai","year":"2025","unstructured":"Tabatabai, G. et al. Treatment of glioblastoma patients with personalized vaccines outside clinical trials: lessons ignored. Neuro Oncol. 27, 302\u2013305 (2025).","journal-title":"Neuro Oncol."},{"key":"960_CR134","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1038\/s41586-022-04489-4","volume":"603","author":"RG Majzner","year":"2022","unstructured":"Majzner, R. G. et al. GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. Nature 603, 934\u2013941 (2022). This clinical trial demonstrates feasibility, safety and signs of clinical efficacy of CAR T cells targeting a glioma antigen in patients with diffuse midline glioma.","journal-title":"Nature"},{"key":"960_CR135","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","volume":"375","author":"CE Brown","year":"2016","unstructured":"Brown, C. E. et al. Regression of glioblastoma after chimeric antigen receptor T-cell therapy. N. Engl. J. Med. 375, 2561\u20132569 (2016).","journal-title":"N. Engl. J. Med."},{"key":"960_CR136","doi-asserted-by":"publisher","first-page":"eaaa0984","DOI":"10.1126\/scitranslmed.aaa0984","volume":"9","author":"DM O\u2019Rourke","year":"2017","unstructured":"O\u2019Rourke, D. M. et al. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci. Transl Med. 9, eaaa0984 (2017).","journal-title":"Sci. Transl Med."},{"key":"960_CR137","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-56547-w","volume":"16","author":"YC Chih","year":"2025","unstructured":"Chih, Y. C. et al. Vaccine-induced T cell receptor T cell therapy targeting a glioblastoma stemness antigen. Nat. Commun. 16, 1262 (2025).","journal-title":"Nat. Commun."},{"key":"960_CR138","doi-asserted-by":"publisher","first-page":"102302","DOI":"10.1016\/j.xcrm.2025.102302","volume":"6","author":"ME Barish","year":"2025","unstructured":"Barish, M. E. et al. Chlorotoxin-directed CAR T cell therapy for recurrent glioblastoma: interim clinical experience demonstrating feasibility and safety. Cell Rep. Med. 6, 102302 (2025).","journal-title":"Cell Rep. Med."},{"key":"960_CR139","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1038\/s41591-024-02893-z","volume":"30","author":"SJ Bagley","year":"2024","unstructured":"Bagley, S. J. et al. Intrathecal bivalent CAR T cells targeting EGFR and IL13R\u03b12 in recurrent glioblastoma: phase 1 trial interim results. Nat. Med. 30, 1320\u20131329 (2024).","journal-title":"Nat. Med."},{"key":"960_CR140","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1038\/s41591-024-02875-1","volume":"30","author":"CE Brown","year":"2024","unstructured":"Brown, C. E. et al. Locoregional delivery of IL-13R\u03b12-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial. Nat. Med. 30, 1001\u20131012 (2024).","journal-title":"Nat. Med."},{"key":"960_CR141","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/s43018-023-00709-6","volume":"5","author":"SJ Bagley","year":"2024","unstructured":"Bagley, S. J. et al. Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab show no efficacy in glioblastoma: a phase 1 trial. Nat. Cancer 5, 517\u2013531 (2024).","journal-title":"Nat. Cancer"},{"key":"960_CR142","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1093\/neuonc\/noac024","volume":"24","author":"CE Brown","year":"2022","unstructured":"Brown, C. E. et al. Off-the-shelf, steroid-resistant, IL13R\u03b12-specific CAR T cells for treatment of glioblastoma. Neuro Oncol. 24, 1318\u20131330 (2022).","journal-title":"Neuro Oncol."},{"key":"960_CR143","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1038\/s41591-021-01404-8","volume":"27","author":"NA Vitanza","year":"2021","unstructured":"Vitanza, N. A. et al. Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis. Nat. Med. 27, 1544\u20131552 (2021).","journal-title":"Nat. Med."},{"key":"960_CR144","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1097\/CJI.0000000000000260","volume":"42","author":"SL Goff","year":"2019","unstructured":"Goff, S. L. et al. Pilot trial of adoptive transfer of chimeric antigen receptor-transduced T cells targeting EGFRvIII in patients with glioblastoma. J. Immunother. 42, 126\u2013135 (2019).","journal-title":"J. Immunother."},{"key":"960_CR145","doi-asserted-by":"publisher","first-page":"eads0449","DOI":"10.1126\/sciimmunol.ads0449","volume":"10","author":"L Bunse","year":"2025","unstructured":"Bunse, L., Bunse, T., Kilian, M., Quintana, F. J. & Platten, M. The immunology of brain tumors. Sci. Immunol. 10, eads0449 (2025).","journal-title":"Sci. Immunol."},{"key":"960_CR146","doi-asserted-by":"publisher","first-page":"eabe7378","DOI":"10.1126\/scitranslmed.abe7378","volume":"13","author":"JH Choe","year":"2021","unstructured":"Choe, J. H. et al. SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma. Sci. Transl Med. 13, eabe7378 (2021).","journal-title":"Sci. Transl Med."},{"key":"960_CR147","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1038\/s41587-019-0192-1","volume":"37","author":"BD Choi","year":"2019","unstructured":"Choi, B. D. et al. CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity. Nat. Biotechnol. 37, 1049\u20131058 (2019).","journal-title":"Nat. Biotechnol."},{"key":"960_CR148","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/s41586-024-08171-9","volume":"637","author":"M Monje","year":"2025","unstructured":"Monje, M. et al. Intravenous and intracranial GD2-CAR T cells for H3K27M+ diffuse midline gliomas. Nature 637, 708\u2013715 (2025).","journal-title":"Nature"},{"key":"960_CR149","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1056\/NEJMoa2314390","volume":"390","author":"BD Choi","year":"2024","unstructured":"Choi, B. D. et al. Intraventricular CARv3-TEAM-E T cells in recurrent glioblastoma. N. Engl. J. Med. 390, 1290\u20131298 (2024). This paper shows, in selected patients from a clinical trial, the feasibility, safety and signs of clinical efficacy of CAR T cells targeting a glioma antigen in patients with glioblastoma secreting a bispecific T cell engager.","journal-title":"N. Engl. J. Med."},{"key":"960_CR150","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1080\/10428194.2025.2458214","volume":"66","author":"S Xiong","year":"2025","unstructured":"Xiong, S., Zhang, S., Yue, N., Cao, J. & Wu, C. CAR-T cell therapy in the treatment of relapsed or refractory primary central nervous system lymphoma: recent advances and challenges. Leuk. Lymphoma 66, 1045\u20131057 (2025).","journal-title":"Leuk. Lymphoma"},{"key":"960_CR151","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1002\/ajh.27316","volume":"99","author":"S Choquet","year":"2024","unstructured":"Choquet, S. et al. CAR T-cell therapy induces a high rate of prolonged remission in relapsed primary CNS lymphoma: real-life results of the LOC network. Am. J. Hematol. 99, 1240\u20131249 (2024).","journal-title":"Am. J. Hematol."},{"key":"960_CR152","doi-asserted-by":"publisher","first-page":"4892","DOI":"10.1158\/1078-0432.CCR-10-1507","volume":"16","author":"JJ Hong","year":"2010","unstructured":"Hong, J. J. et al. Successful treatment of melanoma brain metastases with adoptive cell therapy. Clin. Cancer Res. 16, 4892\u20134898 (2010).","journal-title":"Clin. Cancer Res."},{"key":"960_CR153","doi-asserted-by":"publisher","first-page":"92","DOI":"10.4049\/jimmunol.1301707","volume":"192","author":"Y Fisher","year":"2014","unstructured":"Fisher, Y. et al. Th1 polarization of T cells injected into the cerebrospinal fluid induces brain immunosurveillance. J. Immunol. 192, 92\u2013102 (2014).","journal-title":"J. Immunol."},{"key":"960_CR154","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.tins.2019.07.008","volume":"42","author":"S Mundt","year":"2019","unstructured":"Mundt, S., Greter, M., Flugel, A. & Becher, B. The CNS immune landscape from the viewpoint of a T cell. Trends Neurosci. 42, 667\u2013679 (2019).","journal-title":"Trends Neurosci."},{"key":"960_CR155","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41586-021-04390-6","volume":"602","author":"JJ Melenhorst","year":"2022","unstructured":"Melenhorst, J. J. et al. Decade-long leukaemia remissions with persistence of CD4+ CAR T cells. Nature 602, 503\u2013509 (2022).","journal-title":"Nature"},{"key":"960_CR156","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1126\/science.aay5967","volume":"367","author":"K Reinhard","year":"2020","unstructured":"Reinhard, K. et al. An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors. Science 367, 446\u2013453 (2020). This paper shows that an mRNA vaccine encoding a CAR T cell antigen can induce restimulation, thereby increasing CAR T cell expansion in patients as well as improving homing and tumour control.","journal-title":"Science"},{"key":"960_CR157","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.cell.2020.08.022","volume":"183","author":"KR Parker","year":"2020","unstructured":"Parker, K. R. et al. Single-cell analyses identify brain mural cells expressing CD19 as potential off-tumor targets for CAR-T immunotherapies. Cell 183, 126\u2013142 (2020).","journal-title":"Cell"},{"key":"960_CR158","doi-asserted-by":"publisher","first-page":"444","DOI":"10.3324\/haematol.2022.281110","volume":"108","author":"SC Berger","year":"2023","unstructured":"Berger, S. C. et al. Molecular monitoring of T-cell kinetics and migration in severe neurotoxicity after real-world CD19-specific chimeric antigen receptor T cell therapy. Haematologica 108, 444\u2013456 (2023).","journal-title":"Haematologica"},{"key":"960_CR159","doi-asserted-by":"publisher","first-page":"eadj9730","DOI":"10.1126\/sciimmunol.adj9730","volume":"9","author":"C Qin","year":"2024","unstructured":"Qin, C. et al. Single-cell analysis of anti-BCMA CAR T cell therapy in patients with central nervous system autoimmunity. Sci. Immunol. 9, eadj9730 (2024). This paper shows that CAR T cells targeting a common myeloma antigen can infiltrate the CNS and cause side effects by cross-reacting with neurons expressing low levels of this antigen.","journal-title":"Sci. Immunol."},{"key":"960_CR160","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1038\/s41590-021-00948-8","volume":"22","author":"M Hiltensperger","year":"2021","unstructured":"Hiltensperger, M. et al. Skin and gut imprinted helper T cell subsets exhibit distinct functional phenotypes in central nervous system autoimmunity. Nat. Immunol. 22, 880\u2013892 (2021).","journal-title":"Nat. Immunol."},{"key":"960_CR161","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/nature11337","volume":"488","author":"F Odoardi","year":"2012","unstructured":"Odoardi, F. et al. T cells become licensed in the lung to enter the central nervous system. Nature 488, 675\u2013679 (2012).","journal-title":"Nature"},{"key":"960_CR162","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurot.2024.e00442","volume":"21","author":"N Kawakami","year":"2024","unstructured":"Kawakami, N. & Wekerle, H. Life history of a brain autoreactive T cell: from thymus through intestine to blood-brain barrier and brain lesion. Neurotherapeutics 21, e00442 (2024).","journal-title":"Neurotherapeutics"},{"key":"960_CR163","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1093\/neuonc\/noad087","volume":"25","author":"MC Burger","year":"2023","unstructured":"Burger, M. C. et al. Intracranial injection of natural killer cells engineered with a HER2-targeted chimeric antigen receptor in patients with recurrent glioblastoma. Neuro Oncol. 25, 2058\u20132071 (2023).","journal-title":"Neuro Oncol."},{"key":"960_CR164","doi-asserted-by":"publisher","first-page":"vdad044","DOI":"10.1093\/noajnl\/vdad044","volume":"5","author":"CP Sperring","year":"2023","unstructured":"Sperring, C. P. et al. Convection-enhanced delivery of immunomodulatory therapy for high-grade glioma. Neuro Oncol. Adv. 5, vdad044 (2023).","journal-title":"Neuro Oncol. Adv."},{"key":"960_CR165","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1038\/s41588-022-01236-3","volume":"54","author":"I Liu","year":"2022","unstructured":"Liu, I. et al. The landscape of tumor cell states and spatial organization in H3-K27M mutant diffuse midline glioma across age and location. Nat. Genet. 54, 1881\u20131894 (2022).","journal-title":"Nat. Genet."},{"key":"960_CR166","doi-asserted-by":"publisher","DOI":"10.1002\/cso2.1016","volume":"1","author":"CP Bailey","year":"2021","unstructured":"Bailey, C. P. et al. Computational immune infiltration analysis of pediatric high-grade gliomas (pHGGs) reveals differences in immunosuppression and prognosis by tumor location. Comput. Syst. Oncol. 1, e1016 (2021).","journal-title":"Comput. Syst. Oncol."},{"key":"960_CR167","doi-asserted-by":"publisher","first-page":"102095","DOI":"10.1016\/j.xcrm.2025.102095","volume":"6","author":"JJ LaBelle","year":"2025","unstructured":"LaBelle, J. J. et al. Dissecting the immune landscape in pediatric high-grade glioma reveals cell state changes under therapeutic pressure. Cell Rep. Med. 6, 102095 (2025).","journal-title":"Cell Rep. Med."},{"key":"960_CR168","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-49595-1","volume":"15","author":"AB Levine","year":"2024","unstructured":"Levine, A. B. et al. Immuno-oncologic profiling of pediatric brain tumors reveals major clinical significance of the tumor immune microenvironment. Nat. Commun. 15, 5790 (2024).","journal-title":"Nat. Commun."},{"key":"960_CR169","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/j.cell.2025.12.055","volume":"189","author":"M Meylan","year":"2026","unstructured":"Meylan, M. et al. Persistent T cell activation and cytotoxicity against glioblastoma following single oncolytic virus treatment in a clinical trial. Cell 189, 1287\u20131304 (2026).","journal-title":"Cell"},{"key":"960_CR170","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.medj.2021.01.006","volume":"2","author":"M Kaufmann","year":"2021","unstructured":"Kaufmann, M. et al. Identifying CNS-colonizing T cells as potential therapeutic targets to prevent progression of multiple sclerosis. Med 2, 296\u2013312 (2021).","journal-title":"Med"},{"key":"960_CR171","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1038\/s41593-023-01432-2","volume":"26","author":"A Kendirli","year":"2023","unstructured":"Kendirli, A. et al. A genome-wide in vivo CRISPR screen identifies essential regulators of T cell migration to the CNS in a multiple sclerosis model. Nat. Neurosci. 26, 1713\u20131725 (2023).","journal-title":"Nat. Neurosci."},{"key":"960_CR172","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.3390\/biomedicines10071738","volume":"10","author":"N Elmadany","year":"2022","unstructured":"Elmadany, N., Alhalabi, O. T., Platten, M. & Bunse, L. Site-specific considerations on engineered T cells for malignant gliomas. Biomedicines 10, 1738 (2022).","journal-title":"Biomedicines"},{"key":"960_CR173","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-48326-w","volume":"15","author":"VA Arrieta","year":"2024","unstructured":"Arrieta, V. A. et al. Ultrasound-mediated delivery of doxorubicin to the brain results in immune modulation and improved responses to PD-1 blockade in gliomas. Nat. Commun. 15, 4698 (2024).","journal-title":"Nat. Commun."},{"key":"960_CR174","doi-asserted-by":"publisher","first-page":"4325","DOI":"10.1158\/1078-0432.CCR-20-3760","volume":"27","author":"A Sabbagh","year":"2021","unstructured":"Sabbagh, A. et al. Opening of the blood-brain barrier using low-intensity pulsed ultrasound enhances responses to immunotherapy in preclinical glioma models. Clin. Cancer Res. 27, 4325\u20134337 (2021).","journal-title":"Clin. Cancer Res."},{"key":"960_CR175","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-52329-y","volume":"15","author":"Y Guo","year":"2024","unstructured":"Guo, Y. et al. Ultrasound frequency-controlled microbubble dynamics in brain vessels regulate the enrichment of inflammatory pathways in the blood-brain barrier. Nat. Commun. 15, 8021 (2024). This paper shows that focused ultrasound induces intravascular microbubble disruption to transiently open brain barriers, enabling cytotoxic T cell infiltration into brain tissue.","journal-title":"Nat. Commun."},{"key":"960_CR176","doi-asserted-by":"publisher","first-page":"3032","DOI":"10.1200\/JCO-25-00618","volume":"43","author":"AB Lassman","year":"2025","unstructured":"Lassman, A. B. et al. Dual immune check point blockade in MGMT-unmethylated newly diagnosed glioblastoma: NRG Oncology BN007, a randomized phase II\/III clinical trial. J. Clin. Oncol. 43, 3032\u20133040 (2025).","journal-title":"J. Clin. Oncol."},{"key":"960_CR177","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1093\/neuonc\/noae058","volume":"26","author":"AE Sloan","year":"2024","unstructured":"Sloan, A. E. et al. NRG-BN002: phase I study of ipilimumab, nivolumab, and the combination in patients with newly diagnosed glioblastoma. Neuro Oncol. 26, 1628\u20131637 (2024).","journal-title":"Neuro Oncol."},{"key":"960_CR178","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1093\/neuonc\/noae177","volume":"26","author":"J Duerinck","year":"2024","unstructured":"Duerinck, J. et al. Intracranial administration of anti-PD-1 and anti-CTLA-4 immune checkpoint-blocking monoclonal antibodies in patients with recurrent high-grade glioma. Neuro Oncol. 26, 2208\u20132221 (2024).","journal-title":"Neuro Oncol."},{"key":"960_CR179","doi-asserted-by":"publisher","first-page":"vdad124","DOI":"10.1093\/noajnl\/vdad124","volume":"5","author":"HW Sim","year":"2023","unstructured":"Sim, H. W. et al. NUTMEG: a randomized phase II study of nivolumab and temozolomide versus temozolomide alone in newly diagnosed older patients with glioblastoma. Neuro Oncol. Adv. 5, vdad124 (2023).","journal-title":"Neuro Oncol. Adv."},{"key":"960_CR180","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1001\/jamaoncol.2020.1024","volume":"6","author":"DA Reardon","year":"2020","unstructured":"Reardon, D. A. et al. Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 phase 3 randomized clinical trial. JAMA Oncol. 6, 1003\u20131010 (2020).","journal-title":"JAMA Oncol."},{"key":"960_CR181","doi-asserted-by":"publisher","first-page":"114034","DOI":"10.1016\/j.ejca.2024.114034","volume":"202","author":"A Picca","year":"2024","unstructured":"Picca, A. et al. REVOLUMAB: a phase II trial of nivolumab in recurrent IDH mutant high-grade gliomas. Eur. J. Cancer 202, 114034 (2024).","journal-title":"Eur. J. Cancer"},{"key":"960_CR182","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-54326-7","volume":"15","author":"JR McFaline-Figueroa","year":"2024","unstructured":"McFaline-Figueroa, J. R. et al. Neoadjuvant anti-PD1 immunotherapy for surgically accessible recurrent glioblastoma: clinical and molecular outcomes of a stage 2 single-arm expansion cohort. Nat. Commun. 15, 10757 (2024).","journal-title":"Nat. Commun."},{"key":"960_CR183","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1158\/1078-0432.CCR-24-1629","volume":"31","author":"FM Iwamoto","year":"2025","unstructured":"Iwamoto, F. M. et al. Re-irradiation plus pembrolizumab: a phase II study for patients with recurrent glioblastoma. Clin. Cancer Res. 31, 316\u2013327 (2025).","journal-title":"Clin. Cancer Res."},{"key":"960_CR184","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1093\/neuonc\/noz185","volume":"22","author":"J de Groot","year":"2020","unstructured":"de Groot, J. et al. Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages. Neuro Oncol. 22, 539\u2013549 (2020).","journal-title":"Neuro Oncol."},{"key":"960_CR185","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/s41591-018-0337-7","volume":"25","author":"TF Cloughesy","year":"2019","unstructured":"Cloughesy, T. F. et al. Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat. Med. 25, 477\u2013486 (2019).","journal-title":"Nat. Med."},{"key":"960_CR186","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1038\/s41591-018-0339-5","volume":"25","author":"KA Schalper","year":"2019","unstructured":"Schalper, K. A. et al. Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma. Nat. Med. 25, 470\u2013476 (2019).","journal-title":"Nat. Med."},{"key":"960_CR187","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-56930-7","volume":"16","author":"SP Weathers","year":"2025","unstructured":"Weathers, S. P. et al. Improved overall survival in an anti-PD-L1 treated cohort of newly diagnosed glioblastoma patients is associated with distinct immune, mutation, and gut microbiome features: a single arm prospective phase I\/II trial. Nat. Commun. 16, 3950 (2025).","journal-title":"Nat. Commun."},{"key":"960_CR188","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1200\/JCO.22.00996","volume":"41","author":"MS Ahluwalia","year":"2023","unstructured":"Ahluwalia, M. S. et al. Phase IIa study of SurVaxM plus adjuvant temozolomide for newly diagnosed glioblastoma. J. Clin. Oncol. 41, 1453\u20131465 (2023).","journal-title":"J. Clin. Oncol."},{"key":"960_CR189","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1038\/s43018-025-00998-z","volume":"6","author":"EM Thompson","year":"2025","unstructured":"Thompson, E. M. et al. A peptide vaccine targeting the CMV antigen pp65 in children and young adults with recurrent high-grade glioma and medulloblastoma: a phase 1 trial. Nat. Cancer 6, 1559\u20131569 (2025).","journal-title":"Nat. Cancer"},{"key":"960_CR190","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-48073-y","volume":"15","author":"RG Everson","year":"2024","unstructured":"Everson, R. G. et al. TLR agonists polarize interferon responses in conjunction with dendritic cell vaccination in malignant glioma: a randomized phase II Trial. Nat. Commun. 15, 3882 (2024).","journal-title":"Nat. Commun."},{"key":"960_CR191","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1158\/1078-0432.CCR-21-2867","volume":"28","author":"JL Hu","year":"2022","unstructured":"Hu, J. L. et al. A phase I study of autologous dendritic cell vaccine pulsed with allogeneic stem-like cell line lysate in patients with newly diagnosed or recurrent glioblastoma. Clin. Cancer Res. 28, 689\u2013696 (2022).","journal-title":"Clin. Cancer Res."},{"key":"960_CR192","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1158\/1078-0432.CCR-18-1140","volume":"26","author":"DA Reardon","year":"2020","unstructured":"Reardon, D. A. et al. Rindopepimut with bevacizumab for patients with relapsed EGFRvIII-expressing glioblastoma (ReACT): results of a double-blind randomized phase II trial. Clin. Cancer Res. 26, 1586\u20131594 (2020).","journal-title":"Clin. Cancer Res."},{"key":"960_CR193","doi-asserted-by":"publisher","first-page":"5799","DOI":"10.1158\/1078-0432.CCR-19-0261","volume":"25","author":"PY Wen","year":"2019","unstructured":"Wen, P. Y. et al. A randomized double-blind placebo-controlled phase II trial of dendritic cell vaccine ICT-107 in newly diagnosed patients with glioblastoma. Clin. Cancer Res. 25, 5799\u20135807 (2019).","journal-title":"Clin. Cancer Res."},{"key":"960_CR194","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1093\/neuonc\/noad185","volume":"26","author":"A Saijo","year":"2024","unstructured":"Saijo, A. et al. A combinatory vaccine with IMA950 plus varlilumab promotes effector memory T-cell differentiation in the peripheral blood of patients with low-grade gliomas. Neuro Oncol. 26, 335\u2013347 (2024).","journal-title":"Neuro Oncol."},{"key":"960_CR195","doi-asserted-by":"publisher","first-page":"2778","DOI":"10.1038\/s41591-025-03745-0","volume":"31","author":"SJ Bagley","year":"2025","unstructured":"Bagley, S. J. et al. Intracerebroventricular bivalent CAR T cells targeting EGFR and IL-13R\u03b12 in recurrent glioblastoma: a phase 1 trial. Nat. Med. 31, 2778\u20132787 (2025).","journal-title":"Nat. Med."},{"key":"960_CR196","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-68112-6","volume":"17","author":"X Li","year":"2026","unstructured":"Li, X. et al. Intrathecal CRISPR-edited allogeneic IL-13R\u03b12 CAR T cells for recurrent high-grade glioma: preclinical characterization and phase I trial. Nat. Commun. 17, 1362 (2026).","journal-title":"Nat. Commun."},{"key":"960_CR197","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01711-9","volume":"22","author":"Z Liu","year":"2023","unstructured":"Liu, Z. et al. Safety and antitumor activity of GD2-specific 4SCAR-T cells in patients with glioblastoma. Mol. Cancer 22, 3 (2023).","journal-title":"Mol. Cancer"},{"key":"960_CR198","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1056\/NEJMra0708126","volume":"359","author":"PY Wen","year":"2008","unstructured":"Wen, P. Y. & Kesari, S. Malignant gliomas in adults. N. Engl. J. Med. 359, 492\u2013507 (2008).","journal-title":"N. Engl. J. Med."},{"key":"960_CR199","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis, D. N. et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 23, 1231\u20131251 (2021).","journal-title":"Neuro Oncol."},{"key":"960_CR200","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1056\/NEJMoa0808710","volume":"360","author":"H Yan","year":"2009","unstructured":"Yan, H. et al. IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 360, 765\u2013773 (2009).","journal-title":"N. Engl. J. Med."},{"key":"960_CR201","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/nature08617","volume":"462","author":"L Dang","year":"2009","unstructured":"Dang, L. et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462, 739\u2013744 (2009).","journal-title":"Nature"},{"key":"960_CR202","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.ccr.2010.03.017","volume":"17","author":"H Noushmehr","year":"2010","unstructured":"Noushmehr, H. et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17, 510\u2013522 (2010).","journal-title":"Cancer Cell"},{"key":"960_CR203","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/nature10860","volume":"483","author":"C Lu","year":"2012","unstructured":"Lu, C. et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 483, 474\u2013478 (2012).","journal-title":"Nature"},{"key":"960_CR204","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1093\/neuonc\/noac207","volume":"25","author":"JJ Miller","year":"2023","unstructured":"Miller, J. J. et al. Isocitrate dehydrogenase (IDH) mutant gliomas: a society for neuro-oncology (SNO) consensus review on diagnosis, management, and future directions. Neuro Oncol. 25, 4\u201325 (2023).","journal-title":"Neuro Oncol."},{"key":"960_CR205","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/s41571-021-00521-0","volume":"18","author":"CJ Pirozzi","year":"2021","unstructured":"Pirozzi, C. J. & Yan, H. The implications of IDH mutations for cancer development and therapy. Nat. Rev. Clin. Oncol. 18, 645\u2013661 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"960_CR206","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/s41568-022-00475-0","volume":"22","author":"V Venkataramani","year":"2022","unstructured":"Venkataramani, V. et al. Disconnecting multicellular networks in brain tumours. Nat. Rev. Cancer 22, 481\u2013491 (2022).","journal-title":"Nat. Rev. Cancer"},{"key":"960_CR207","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/nature16071","volume":"528","author":"M Osswald","year":"2015","unstructured":"Osswald, M. et al. Brain tumour cells interconnect to a functional and resistant network. Nature 528, 93\u201398 (2015).","journal-title":"Nature"},{"key":"960_CR208","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1038\/s41588-025-02168-4","volume":"57","author":"A Spitzer","year":"2025","unstructured":"Spitzer, A. et al. Deciphering the longitudinal trajectories of glioblastoma ecosystems by integrative single-cell genomics. Nat. Genet. 57, 1168\u20131178\u00a0(2025).","journal-title":"Nat. Genet."},{"key":"960_CR209","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1016\/j.cell.2024.03.029","volume":"187","author":"AC Greenwald","year":"2024","unstructured":"Greenwald, A. C. et al. Integrative spatial analysis reveals a multi-layered organization of glioblastoma. Cell 187, 2485\u20132501 (2024).","journal-title":"Cell"},{"key":"960_CR210","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/nri2807","volume":"10","author":"GW Litman","year":"2010","unstructured":"Litman, G. W., Rast, J. P. & Fugmann, S. D. The origins of vertebrate adaptive immunity. Nat. Rev. Immunol. 10, 543\u2013553 (2010).","journal-title":"Nat. Rev. Immunol."},{"key":"960_CR211","unstructured":"Abbas, A. Lichtman, A. & Pillai, S. Cellular and Molecular Immunology 9th edn (Elsevier, 2018)."},{"key":"960_CR212","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1038\/ni.f.208","volume":"9","author":"H Sigmundsdottir","year":"2008","unstructured":"Sigmundsdottir, H. & Butcher, E. C. Environmental cues, dendritic cells and the programming of tissue-selective lymphocyte trafficking. Nat. Immunol. 9, 981\u2013987 (2008).","journal-title":"Nat. Immunol."},{"key":"960_CR213","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/imr.12650","volume":"283","author":"T Gebhardt","year":"2018","unstructured":"Gebhardt, T., Palendira, U., Tscharke, D. C. & Bedoui, S. Tissue-resident memory T cells in tissue homeostasis, persistent infection, and cancer surveillance. Immunol. Rev. 283, 54\u201376 (2018).","journal-title":"Immunol. Rev."},{"key":"960_CR214","doi-asserted-by":"publisher","first-page":"eaas9673","DOI":"10.1126\/sciimmunol.aas9673","volume":"4","author":"PA Szabo","year":"2019","unstructured":"Szabo, P. A., Miron, M. & Farber, D. L. Location, location, location: tissue resident memory T cells in mice and humans. Sci. Immunol. 4, eaas9673 (2019).","journal-title":"Sci. Immunol."}],"container-title":["Nature Reviews Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41568-026-00960-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41568-026-00960-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41568-026-00960-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T12:01:41Z","timestamp":1792756901000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41568-026-00960-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,20]]},"references-count":214,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["960"],"URL":"https:\/\/doi.org\/10.1038\/s41568-026-00960-w","relation":{},"ISSN":["1474-175X","1474-1768"],"issn-type":[{"value":"1474-175X","type":"print"},{"value":"1474-1768","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,20]]},"assertion":[{"value":"30 June 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.P. is an inventor and patent holder on \u2018Peptides for use in treating or diagnosing IDH1R132H positive cancers\u2019 (EP2800580B1), on \u2018Method for the detection of antigen presentation\u2019 (US20170254803A1) and \u2018Histone anticancer vaccines\u2019 (WO2017009349A1), on \u2018T cell receptor binding polypeptides\u2019 (PCT\/EP2023\/061716) and \u2018T cell\u2013NK cell interaction inhibitors for use in disease treatment\u2019 (PCT\/EP2023\/080370 and WO2024\/104777A1) and on \u2018Antigen reactive T cell receptors\u2019 (EP21164371.3, WO2022200456A1, EP2022057672W and PCT\/EP2025\/053849). He is a founder of Tcelltech GmbH. He has received research support from Servier, Pfizer, Merck, Bayer, and Roche (institutional) and consulting honoraria from Servier (institutional) and Cellula.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}